Similarly, NSCLC patients with NOTCH4 mutations had a better response rate to ICI and better overall survival [113], and mutations in the Notch pathway, as well as in DNA damage response, coincided with durable clinical benefit in NSCLC [114,115]. The gene discussed is NOTCH4; the disease is non-small cell lung carcinoma.